-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

Benzinga·10/06/2026 14:55:09
Listen to the news
JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.